Figma Shares Indicated To Open $105/$110
In a recent transaction, Scott Alan Samuels, Executive Vice President and Chief Legal Officer of Geron Corp (NASDAQ:GERN), purchased 15,000 shares of the company’s common stock. The shares were acquired at an average price of $1.61 each, totaling approximately $24,150. According to InvestingPro data, this purchase comes as the stock trades significantly below its 52-week high of $5.34, with shares down about 60% over the past six months. This transaction, which took place on February 27, 2025, increased Samuels’ direct ownership to 26,682 shares. The acquisition was part of an open market purchase, reflecting Samuels’ growing investment in the pharmaceutical company. InvestingPro analysis indicates the stock is currently undervalued, with analyst price targets ranging from $2 to $7. Discover 12 additional key insights about GERN with an InvestingPro subscription, including detailed financial health metrics and growth prospects.
In other recent news, Geron Corporation reported fourth-quarter 2024 net product revenue of $47.5 million, which slightly exceeded internal estimates but fell short of the anticipated $61.93 million. Despite surpassing some expectations, the earnings per share (EPS) of ($0.04) missed the consensus estimate by $0.01, leading to investor concerns. Analysts from Stifel, Scotiabank (TSX:BNS), H.C. Wainwright, and TD Cowen have adjusted their price targets for Geron, citing various strategic and market challenges. Both Stifel and Scotiabank reduced their price targets to $4, maintaining a Buy and Sector Outperform rating, respectively. H.C. Wainwright downgraded Geron from a Buy to a Neutral rating due to a plateau in sales and revised revenue projections, while TD Cowen lowered its target to $5 but kept a Buy rating. The company has faced scrutiny over its drug Rytelo, with analysts noting a slowdown in its market momentum and patient adoption. Geron plans to address these challenges through increased physician engagement and strategic marketing efforts. Despite the hurdles, the company remains optimistic about Rytelo’s potential in treating lower-risk myelodysplastic syndromes (LR-MDS).
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.